EP2967850A1 - Appareil perfectionné à feuillet et valvule - Google Patents
Appareil perfectionné à feuillet et valvuleInfo
- Publication number
- EP2967850A1 EP2967850A1 EP14708735.7A EP14708735A EP2967850A1 EP 2967850 A1 EP2967850 A1 EP 2967850A1 EP 14708735 A EP14708735 A EP 14708735A EP 2967850 A1 EP2967850 A1 EP 2967850A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- leaflet
- prosthetic valve
- guiding element
- valve
- layers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002313 fluoropolymer Polymers 0.000 claims description 50
- 239000004811 fluoropolymer Substances 0.000 claims description 50
- 239000002131 composite material Substances 0.000 claims description 44
- 239000000463 material Substances 0.000 claims description 42
- 229920001971 elastomer Polymers 0.000 claims description 40
- 239000000806 elastomer Substances 0.000 claims description 40
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 31
- 239000011148 porous material Substances 0.000 claims description 24
- 229920001973 fluoroelastomer Polymers 0.000 claims description 15
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 12
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- 239000012781 shape memory material Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 6
- 239000007769 metal material Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 description 66
- 239000010410 layer Substances 0.000 description 56
- 210000004379 membrane Anatomy 0.000 description 44
- 238000000034 method Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 238000005452 bending Methods 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 210000003709 heart valve Anatomy 0.000 description 15
- 230000000004 hemodynamic effect Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 10
- 239000000560 biocompatible material Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 238000009958 sewing Methods 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000006835 compression Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 239000013536 elastomeric material Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229910001000 nickel titanium Inorganic materials 0.000 description 5
- BLTXWCKMNMYXEA-UHFFFAOYSA-N 1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)OC(F)(F)F BLTXWCKMNMYXEA-UHFFFAOYSA-N 0.000 description 4
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 4
- 229920009441 perflouroethylene propylene Polymers 0.000 description 4
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 238000007669 thermal treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910000990 Ni alloy Inorganic materials 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZGDWHDKHJKZZIQ-UHFFFAOYSA-N cobalt nickel Chemical compound [Co].[Ni].[Ni].[Ni] ZGDWHDKHJKZZIQ-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011256 inorganic filler Substances 0.000 description 2
- 229910003475 inorganic filler Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010068165 Cardiac valve rupture Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 239000004687 Nylon copolymer Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012282 endovascular technique Methods 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- FHTQCUNSKSWOHF-UHFFFAOYSA-N ethyl carbamate;silicon Chemical compound [Si].CCOC(N)=O FHTQCUNSKSWOHF-UHFFFAOYSA-N 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0029—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in bending or flexure capacity
Definitions
- Valve durability under the repetitive loads of the leaflets opening and closing is dependent, in part, on the dynamic characteristics of the leaflets. Thin leaflets can develop folds that repeatedly form in the central portion of the leaflet during the opening and closing action of the valve, often times resulting in the formation of a hole within the leaflet at a site of repeated bending stress.
- the present invention comprises apparatus and systems for valve replacement or augmentation, such as cardiac valve replacement.
- the present invention is directed towards leaflet design or modifications and leaflet-type cardiac valves that not only improve upon conventional prosthetic valve hemodynamics, but also reduce the incidence of premature leaflet failure. Stated otherwise, the leaflet designs contemplated herein demonstrate improved performance and improved longevity in valve leaflets that would otherwise exhibit tight-radius buckling.
- a prosthetic valve comprises a frame, at least one leaflet, and a guiding element.
- Each leaflet comprises a plurality of layers of film coupled together.
- Each leaflet defines a leaflet base, a leaflet edge portion opposite the leaflet base, and a central portion between the leaflet base and the leaflet edge portion.
- Each leaflet is coupled to the frame along at least a portion of the leaflet base.
- Each leaflet is pivotable between an open position and a closed position.
- the central portion has a greater stiffness than at least one of the leaflet edge portion and the leaflet base.
- the one or more guiding elements have a length which is aligned radiating away from but spaced apart from the leaflet base such that the leaflet pivots substantially from the leaflet base when the leaflet is deployed in the prosthetic valve and the prosthetic valve is operated so as to flex the leaflet.
- FIG. 1 A is a top view of an embodiment of a valve in a closed
- FIG. 1B is an axial view of an embodiment of the valve of FIG. 1A in an open configuration, in accordance with an embodiment
- FIG. 2 is a perspective view of an embodiment of a valve in a closed configuration, in accordance with an embodiment
- FIG. 5 is an axial view of an embodiment of a valve having leaflets comprising a guiding element, in accordance with an embodiment
- FIG. 12 is a cross-sectional view of a guiding element between layers of film, in accordance with an embodiment
- embodiments within the scope of this disclosure can be applied toward any valve or mechanism of similar structure and/or function. Furthermore, embodiments within the scope of this disclosure can be applied in non -cardiac applications.
- composite material refers to a combination of a membrane, such as, but not limited to, expanded fluoropolymer, and an elastomer, such as, but not limited to, a fluoroelastomer.
- a membrane such as, but not limited to, expanded fluoropolymer
- an elastomer such as, but not limited to, a fluoroelastomer.
- the elastomer can be imbibed within a porous structure of the membrane, coated on one or both sides of the membrane, or a combination of coated on and imbibed within the membrane.
- T e term laminate refers to multiple layers of membrane, composite material, or other materials, such as elastomer, and combinations thereof.
- film as used herein generically refers to one or more of the membrane, composite material, or laminate.
- leaflet window is defined as that space that a frame defines from which a leaflet extends.
- the leaflet may extend from frame elements or adjacent to frame elements and spaced apart therefrom.
- native valve orifice and tissue orifice refer to an anatomical structure into which a prosthetic valve may be placed.
- Such anatomical structure includes, but is not limited to, a location wherein a cardiac valve may or may not have been surgically removed.
- other anatomical structures that can receive a prosthetic valve include, but are not limited to, veins, arteries, ducts and shunts.
- a valve orifice or implant site may also refer to a location in a synthetic or biological conduit that may receive a valve.
- Couple means to join, connect, attach, adhere, affix, or bond, whether directly or indirectly, and whether permanently or temporarily.
- leaflet embodiments presented herein provide improved leaflet bending, and thereby improved lifetime and improved hemodynamics.
- Embodiments provided herein are related to prosthetic heart valve leaflets comprising one or more guiding elements that allow for control of the movement of the leaflets, such as, but not limited to, controlling the bending characteristics of the leaflet.
- a prosthetic valve comprises a plurality of polymer leaflets.
- the polymer leaflets comprise a laminate of multiple layers of membrane, composite material, or other materials, such as elastomer, and combinations thereof.
- One or more guiding elements are coupled to and contained within the laminate lying between two of the multiple layers of membrane or composite material.
- the guiding element is operable to provide a structural influence on the leaflet such as to control the bending characteristics of the leaflet. Since the guiding element is fully contained within the laminate layers, the guiding element remains permanently coupled to the leaflet. Further, since the guiding element is fully contained within the laminate layers, the guiding element is not exposed to the blood stream.
- FIG. 1 Another embodiment is directed towards a prosthetic valve comprising a leaflet support member and at least one leaflet as described above wherein the leaflet is connected to the support member along the base portion of the leaflet.
- the leaflet is movable between a first position and a second position, such that in the first position, the valve is a flow occluder and in the second position, the valve is a flow orifice.
- the valve further comprises a guiding element, as described herein, connected to at least one leaflet.
- at least one leaflet 140 may not have a guiding element 150, while at least one leaflet does comprise a guiding element 150.
- the valve comprises a compressed configuration and an expanded configuration.
- a valve can be compressible or crushable under the application of a binding or compression force to obtain a compressed configuration.
- a support member may comprise a shape memory material.
- a compressible valve may be implanted via endovascular techniques now known or hereinafter derived.
- FIGS. 1 A and 1 B are axial views of a valve 100 in the closed and open condition, respectively, in accordance with an embodiment.
- FIG. 2 is a perspective view of the valve 100 in the closed condition.
- the valve 100 comprises a frame 130 and a film 160 covering the frame 130 forming the leaflets 140 coupled to the frame 130, in accordance with an embodiment.
- FIG. 3 is a perspective view of the frame 130, in accordance with an embodiment.
- a film 160 generically refers to one or more of the membrane, composite material, or laminate as previously defined.
- the leaflets 140 are comprised of the film 160. Details of various types of film 160 are discussed below.
- the film 160 can be formed from a generally tubular material to couple the frame 130 and to form the leaflets 140.
- the laminate comprises a number of layers of membrane and/or composite material, with the guiding element 150 being coupled and contained within at least two layers of membrane and/or composite material.
- the film 160 comprises a biocompatible polymer that is combined with an elastomer, referred to as a composite.
- a material according to one embodiment includes a composite material comprising an expanded
- fluoropolymer membrane which comprises a plurality of spaces within a matrix of fibrils, and an elastomeric material.
- elastomeric material can include multiple elastomers, multiple types of non-elastomeric components, such as inorganic fillers, therapeutic agents, radiopaque materials, and the like while remaining within the scope of the present disclosure.
- the expanded fluoropolymer membrane can comprise any suitable microstructure for achieving the desired leaflet performance.
- the expanded fluoropolymer comprises a microstructure of nodes interconnected by fibrils, such as described in U.S. Patent No. 3,953,566 to Gore.
- the fibrils radiaHy extend from the nodes in a plurality of directions, and the membrane has a generally homogeneous structure.
- Membranes having this microstructure may typically exhibit a ratio of matrix tensile strength in two orthogonal directions of less than 2, and possibly less than 1.5.
- the expanded fluoropolymer membrane can be tailored to have any suitable thickness and mass to achieve the desired leaflet performance.
- the leaflet 140 comprises an expanded
- the expanded fluoropolymer membrane having a thickness of about 0.1 ⁇ .
- the expanded fluoropolymer membrane can possess a mass per area of about 1.15 g m 2 .
- Membranes according to an embodiment of the invention can have matrix tensile strengths of about 411 MPa in the longitudinal direction and 315 MPa in the transverse direction.
- a method of filling the pores of the expanded fluoropolymer membrane includes the steps of polymerizing the elastomer within the pores of the expanded fluoropolymer membrane by first filling the pores with a prepolymer of the elastomer and then at least partially curing the elastomer.
- the leaflets constructed from fluoropolymer materials or ePTFE generally performed better with increasing percentages of elastomer resulting in significantly increased cycle lives.
- the elastomer combined with the ePTFE is a thermoplastic copolymer of tetrafluoroethylene and perfluoromethyl vinyl ether, such as described in U.S. Patent No. 7,462,675 to Chang et al., and other references that would be known to those of skill in the art.
- FIG. 3 is a perspective view of the frame 130 in the embodiment of FIGS. 1 A and 1 B.
- the frame 130 is a generally tubular member defining a valve orifice 102 and providing structural, load-bearing support to the leaflet 140.
- the frame 130 can be configured to provide positive engagement to the recipient tissue at the implantation site.
- the frame 130 can comprise any metallic or polymeric biocompatible material.
- the frame 130 can comprise a material, such as, but not limited to nitinol, cobalt-nickel alloy, stainless steel, and polypropylene, acetyl homopolymer, acetyl copolymer, ePTFE, other alloys or polymers, or any other biocompatible material having adequate physical and mechanical properties to function as described herein.
- the frame 130 defines a stent having apertures 122.
- the open framework of the stent can define any number of features, repeatable or otherwise, such as geometric shapes and/or linear or meandering series of sinusoids.
- An open framework can be etched, cut, laser cut, or stamped into a tube or a sheet of material, with the sheet then formed into a substantially cylindrical structure.
- the frame 130 can have a solid wall.
- an elongated material such as a wire, bendable strip, or a series thereof, can be bent or braided and formed into a substantially cylindrical structure.
- the frame 130 can comprise, such as, but not limited to, an elastically deformable metallic or polymeric biocompatible material.
- the frame 130 can comprise a shape-memory material, such as nitinol, a nickel-titanium alloy.
- Other materials suitable for the frame 130 include, but not limited to, other titanium alloys, stainless steel, cobalt-nickel alloy, polypropylene, acetyl homopolymer, acetyl copolymer, other alloys or polymers, or any other biocompatible material having adequate physical and mechanical properties to function as a frame 130 as described herein.
- the film 160 can be coupled to the frame 130 in many ways suitable for a particular purpose.
- the frame 130 can be wrapped with overlapping layers of the film 160.
- the film 160 can be coupled to the frame outside surface 133a or the frame inside surface 133b of the frame 130. In another embodiment, the film 160 can be coupled to either of the frame outside surface 133a or the frame inside surface 133b.
- the film 160 is fixedly secured or otherwise coupled at a single or a plurality of locations of the frame outside surface 133a and the frame inside surface 133b of the frame 130, for example, using one or more of taping, heat shrinking, adhesion and other processes known in the art.
- a plurality of membrane composite layers such as, but not limited to a laminate, are used and can be coupled to the frame 130 to form at least a portion of the film 160.
- Fluid flow is permitted through the valve orifice 102 when the leaflets 140 are in an open position as shown in FIG. 1 B.
- the leaflets 140 generally flex about the base 134 of the U-shaped portion 132 as the leaflets 140 open and close, as shown in FIG. 3.
- when the valve 100 is closed generally about half of each leaflet free edge 142 abuts an adjacent half of a leaflet free edge 142 of an adjacent leaflet 140, as shown in FIG. 2.
- a leaflet thickness may range from about 10 m to about 100 pm but again such thickness may vary from the above stated ranges depending on the size, material, and desired function of the leaflet. As discussed below, improvements in accordance with the present embodiments may provide for leaflet thicknesses outside of conventional thicknesses.
- FIG. 5 is an axial view of a representation of a valve 101.
- a leaflet edge portion 113 comprises a coaptation region 146 of the leaflet 140.
- a central portion 147 comprises an area between a leaflet base 135 and the leaflet edge portion 113.
- a coaptation region 146 is the area comprising the junction formed between two leaflets 140 in the closed position.
- the leaflet 140 also comprises a vertical axis X1.
- the height of the leaflet 140 is the length of the leaflet 140 along a line parallel to the vertical axis X1.
- the width of the leaflet 140 is the length of the leaflet 140 along a line perpendicular to the vertical axis X1 , which may vary between the leaflet base 135 and the leaflet free edge 142.
- the guiding element defines a guiding element length and the leaflet defines a leaflet length extending from the leaflet base and the edge portion, the guiding element length being less than the leaflet length.
- the guiding element improves both the longevity, such as, but not limited to, durability, and the hemodynamic performance of the valve.
- the motion of the central portion 147 of the leaflet 140 between the first position and the second position substantially follows the guiding element 150.
- the amplitude or number of sigmoid, or S-shaped, curves formed on the leaflet about the vertical axis X1 during the transition may be reduced, and a majority of such curves are formed closer to the leaflet edge portion 113 and the leaflet base 135 of the leaflet 140 and in a more controlled manner.
- the motion of a point on the guiding element 150 may exist substantially on a plane, substantially on an arc, and in an embodiment, substantially on an elliptical arc.
- the motion of the guiding element 150 as a whole tracks a substantially planar pivoting surface while transitioning between the first position and the second position.
- the guiding element 150 may comprise a plurality of materials, and thereby exhibit a variable resistance to deformation along its length or width.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Manufacturing & Machinery (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361800402P | 2013-03-15 | 2013-03-15 | |
US14/183,251 US20140163671A1 (en) | 2011-04-01 | 2014-02-18 | Leaflet and valve apparatus |
PCT/US2014/017118 WO2014149319A1 (fr) | 2013-03-15 | 2014-02-19 | Appareil perfectionné à feuillet et valvule |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2967850A1 true EP2967850A1 (fr) | 2016-01-20 |
Family
ID=50238472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14708735.7A Withdrawn EP2967850A1 (fr) | 2013-03-15 | 2014-02-19 | Appareil perfectionné à feuillet et valvule |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2967850A1 (fr) |
JP (1) | JP2016510645A (fr) |
KR (1) | KR20150130300A (fr) |
CN (1) | CN105050544A (fr) |
AU (1) | AU2014238323B2 (fr) |
CA (1) | CA2900676A1 (fr) |
HK (1) | HK1215999A1 (fr) |
WO (1) | WO2014149319A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104780952A (zh) | 2012-07-02 | 2015-07-15 | 波士顿科学医学有限公司 | 假体心脏瓣膜形成 |
US10376360B2 (en) | 2012-07-27 | 2019-08-13 | W. L. Gore & Associates, Inc. | Multi-frame prosthetic valve apparatus and methods |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US10299915B2 (en) | 2015-04-09 | 2019-05-28 | Boston Scientific Scimed, Inc. | Synthetic heart valves composed of zwitterionic polymers |
US10426609B2 (en) | 2015-04-09 | 2019-10-01 | Boston Scientific Scimed, Inc. | Fiber reinforced prosthetic heart valve having undulating fibers |
US10314696B2 (en) | 2015-04-09 | 2019-06-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valves having fiber reinforced leaflets |
US10716671B2 (en) | 2015-07-02 | 2020-07-21 | Boston Scientific Scimed, Inc. | Prosthetic heart valve composed of composite fibers |
US10413403B2 (en) | 2015-07-14 | 2019-09-17 | Boston Scientific Scimed, Inc. | Prosthetic heart valve including self-reinforced composite leaflets |
US10195023B2 (en) | 2015-09-15 | 2019-02-05 | Boston Scientific Scimed, Inc. | Prosthetic heart valves including pre-stressed fibers |
US10022223B2 (en) | 2015-10-06 | 2018-07-17 | W. L. Gore & Associates, Inc. | Leaflet support devices and methods of making and using the same |
CN109475409B (zh) | 2016-05-19 | 2021-02-19 | 波士顿科学国际有限公司 | 人工瓣膜、瓣膜小叶和相关方法 |
JP6946464B2 (ja) | 2017-04-25 | 2021-10-06 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 生体適合性ポリイソブチレン−繊維複合材料及び方法 |
AU2018334191B2 (en) | 2017-09-12 | 2021-04-08 | Edwards Lifesciences Corporation | Leaflet frame attachment for prosthetic valves |
CA3072814C (fr) | 2017-09-27 | 2023-01-03 | W.L. Gore & Associates, Inc. | Valvule prothetique a cadre extensible et systemes et procedes associes |
CN115024861A (zh) | 2017-09-27 | 2022-09-09 | W.L.戈尔及同仁股份有限公司 | 具有机械联接的瓣叶的假体瓣膜 |
CN111447890B (zh) | 2017-10-13 | 2023-01-31 | W.L.戈尔及同仁股份有限公司 | 叠套式假体瓣膜及递送系统 |
JP7052032B2 (ja) | 2017-10-31 | 2022-04-11 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 組織内方成長を促進する医療用弁及び弁膜 |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
AU2020270993B2 (en) * | 2019-04-12 | 2023-11-23 | Edwards Lifesciences Corporation | Valve with multi-part frame and associated resilient bridging features |
WO2023133724A1 (fr) * | 2022-01-12 | 2023-07-20 | 金仕生物科技(常熟)有限公司 | Valve d'intervention pouvant être implantée sous guidage d'imagerie ultrasonore |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6283994B1 (en) * | 1999-04-16 | 2001-09-04 | Sulzer Carbomedics Inc. | Heart valve leaflet |
JP2004510471A (ja) * | 2000-09-21 | 2004-04-08 | セント・ジュード・メディカル・インコーポレーテッド | 強化されたポリマーリーフレットを有する弁プロテーゼ |
US6602286B1 (en) * | 2000-10-26 | 2003-08-05 | Ernst Peter Strecker | Implantable valve system |
US20120116496A1 (en) * | 2010-11-05 | 2012-05-10 | Chuter Timothy A | Stent structures for use with valve replacements |
EP2522308B1 (fr) * | 2011-05-10 | 2015-02-25 | Biotronik AG | Prothèse de valvule mécanique à transcathéter |
-
2014
- 2014-02-19 AU AU2014238323A patent/AU2014238323B2/en not_active Ceased
- 2014-02-19 WO PCT/US2014/017118 patent/WO2014149319A1/fr active Application Filing
- 2014-02-19 CA CA2900676A patent/CA2900676A1/fr not_active Abandoned
- 2014-02-19 KR KR1020157025135A patent/KR20150130300A/ko not_active Application Discontinuation
- 2014-02-19 EP EP14708735.7A patent/EP2967850A1/fr not_active Withdrawn
- 2014-02-19 CN CN201480015174.3A patent/CN105050544A/zh active Pending
- 2014-02-19 JP JP2016500300A patent/JP2016510645A/ja active Pending
-
2016
- 2016-04-07 HK HK16103928.3A patent/HK1215999A1/zh unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2014149319A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014238323A1 (en) | 2015-08-20 |
KR20150130300A (ko) | 2015-11-23 |
WO2014149319A1 (fr) | 2014-09-25 |
CN105050544A (zh) | 2015-11-11 |
JP2016510645A (ja) | 2016-04-11 |
AU2014238323B2 (en) | 2017-03-09 |
CA2900676A1 (fr) | 2014-09-25 |
HK1215999A1 (zh) | 2016-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014238323B2 (en) | Improved leaflet and valve apparatus | |
US20140163671A1 (en) | Leaflet and valve apparatus | |
US20240156589A1 (en) | Methods for improved prosthetic heart valve with leaflet shelving | |
US20210205074A1 (en) | Geometric control of bending character in prosthetic heart valve leaflets | |
US11039917B2 (en) | Geometric prosthetic heart valves | |
US20210121289A1 (en) | Prosthetic valves, frames and leaflets and methods thereof | |
US20190269505A1 (en) | Multi-frame prosthetic heart valve | |
WO2014149295A1 (fr) | Lame valvulaire cardiaque prothétique conçue pour une imagerie externe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150921 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1215999 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20180606 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1215999 Country of ref document: HK |